Home Applications 210132 Application 210132
Type NDA
Sponsor THERAPEUTICSMD INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 BIJUVA ESTRADIOL; PROGESTERONE CAPSULE;ORAL 1MG;100MG Yes Yes 002 BIJUVA ESTRADIOL; PROGESTERONE CAPSULE;ORAL 0.5MG;100MG Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N210132-001 BIJUVA ESTRADIOL; PROGESTERONE 1MG;100MG CAPSULE / ORAL RLD, RS 2018-10-28 N210132-002 BIJUVA ESTRADIOL; PROGESTERONE 0.5MG;100MG CAPSULE / ORAL RLD 2021-12-28
Orange Book patents# Current patent rows page 1 of 1 · 39 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 3 of 3 · 81 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N210132-002 BIJUVA 0.5MG;100MG CAPSULE / ORAL RLD 2021-12-28 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 37 · 1,464 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N210132-001 10052386 2032-11-21 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 10206932 2032-11-21 U-2439 2019-03-11 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 10639375 2032-11-21 Drug product 2020-05-12 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 10675288 2032-11-21 U-2439 2020-06-10 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 10806740 2032-11-21 U-2439 Drug product 2020-10-30 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 11033626 2032-11-21 U-2439 Drug product 2021-07-13 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 11103513 2032-11-21 U-2439 2021-09-23 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 11103516 2032-11-21 Drug product 2021-09-23 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 11110099 2032-11-21 Drug product 2021-09-23 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 11529360 2032-11-21 Drug product 2022-12-21 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 11793819 2032-11-21 U-2439 2023-11-14 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 11865179 2032-11-21 Drug substance, Drug product 2024-02-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 8633178 2032-11-21 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 8846648 2032-11-21 U-2439 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 8846649 2032-11-21 U-2439 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 8987237 2032-11-21 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 8993548 2032-11-21 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 8993549 2032-11-21 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 9006222 2032-11-21 U-2439 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 9114145 2032-11-21 U-2439 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 9114146 2032-11-21 U-2439 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-001 9301920 2032-11-21 U-2439 Drug product 2018-11-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 10052386 2032-11-21 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 10206932 2032-11-21 U-2439 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 10675288 2032-11-21 U-2439 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 11033626 2032-11-21 U-2439 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 11166963 2032-11-21 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 11793819 2032-11-21 U-2439 2023-11-14 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 11865179 2032-11-21 Drug substance, Drug product 2024-02-01 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 8633178 2032-11-21 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 8846648 2032-11-21 U-2439 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 8846649 2032-11-21 U-2439 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 8933059 2032-11-21 U-2439 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 8987237 2032-11-21 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 8993548 2032-11-21 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 8993549 2032-11-21 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 9114145 2032-11-21 U-2439 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 9114146 2032-11-21 U-2439 Drug product 2022-01-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210132-002 9301920 2032-11-21 U-2439 Drug product 2022-01-26 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N210132-001 10052386 2032-11-21 Drug product 2018-11-19 c2088c7a36db…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 6 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 50261-211 Bijuva estradiol and progesterone TherapeuticsMD, Inc. NDA Current 50261-211 Bijuva estradiol and progesterone TherapeuticsMD, Inc. NDA Current 50261-211 Bijuva estradiol and progesterone TherapeuticsMD, Inc. NDA Current 50261-211 Bijuva estradiol and progesterone TherapeuticsMD, Inc. NDA Current 50261-211 Bijuva estradiol and progesterone TherapeuticsMD, Inc. NDA Current 50261-211 Bijuva estradiol and progesterone TherapeuticsMD, Inc. NDA Current